In The News
NAB super trustee entitled to pay adviser commissions, class action judge says
Builder and developer off the hook for $3M in fire safety repairs
Coles, Woolworths say price increases were genuine, and so were the discounts
Start-up denies ex-Fortescue employees developed green iron process on company dime
In class action defence, Toyota says ‘defeat device’ used to protect engines
Hamilton Locke loses challenge to Sydney law firm’s trade mark
Solve My Debt Now to admit liability in ASIC proceedings
Maddocks lures leading competition lawyer from Johnson Winter Slattery
Class action against NAB super fund trustee fails
Property investment firm found negligent for Perth development promises
Please login to bookmarkClose

A GlaxoSmithKline unit has defeated Nova Pharmaceuticals’ bid to trade mark ‘Novadart’ for a generic version of the British company’s market-leading drug prostate drug ‘Avodart’, with a delegate finding the mark would cause consumer confusion.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au